UNSPSC 51151607: Clidinium

This classification denotes an antimuscarinic agent with the molecular formula C22H26NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BO76JF850N, chemically known as 1-azoniabicyclo(2.2.2)octane, 3-((hydroxydiphenylacetyl)oxy)-1-methyl- but generally known as clidinium, which bears US NIH Compound Identifier 2784. European Medicines Agency schedules Clidinium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13391MIG.

CLIDINIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, CLIDINIUM remains the US FDA Preferred Term for this commodity. Clidinium bears US NLM identifiers UMLS ID C0055877 and NCI Concept Code C73138. SMILES: O(C1C2CC[N](C1)(CC2)C)C(=O)C(O)(C1CCCCC1)C1CCCCC1.

UNSPSC 51151607 Clidinium (Commodity) covers pharmaceutical products, though recent state and local solicitations tagged under this code reflect procurement of naloxone, safe drug deactivation systems, and pharmacy benefit program services rather than clidinium specifically. State and local health agencies and human services commissions use this code to acquire medications and drug-management products supporting community health, emergency response, and pharmacy benefit administration. Issuing bodies include county health departments, state health and human services agencies, and their contracted pharmacy benefit vendors. The scope spans both direct pharmaceutical procurement and broader pharmacy program design services, including vendor capacity assessment for direct-to-manufacturer prescription models.

Recent activity centers on Florida and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the bid deadline was July 26, 2023, with electronic submission through the county's e-Procurement Portal and fixed-fee pricing. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information from potential vendors on direct contracting experience with self-insured employers and health plans, negotiated net pricing models without rebates, and value-based or outcomes-based agreement implementation; this preliminary RFI closes the information-gathering phase before a formal RFP. Both opportunities carry standard compliance requirements including drug-free workplace certification, E-Verify, and insurance coverage mandates; the Seminole County contract includes a three-month probationary termination clause.